H. Lundbeck A/S (Lundbeck) today announced that new pipeline data regarding bexicaserin (LP352), a novel investigational drug for the treatment of seizures associated with Developmental and Epileptic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback